NASDAQ:SBPHSpring Bank Pharmaceuticals Stock Price, Forecast & News

Spring Bank Pharmaceuticals' stock was trading at $1.16 on March 11th, 2020 when COVID-19 reached pandemic status according to the World Health Organization (WHO). Since then, SBPH stock has increased by 42.2% and is now trading at $1.65. View which stocks have been most impacted by Coronavirus.

4 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Spring Bank Pharmaceuticals in the last year. There are currently 3 hold ratings and 1 buy rating for the stock, resulting in a consensus recommendation of "Hold." View analyst ratings for Spring Bank Pharmaceuticals.

Spring Bank Pharmaceuticals is scheduled to release its next quarterly earnings announcement on Wednesday, July 29th 2020. View our earnings forecast for Spring Bank Pharmaceuticals.

Spring Bank Pharmaceuticals Inc (NASDAQ:SBPH) announced its quarterly earnings results on Thursday, May, 7th. The company reported ($0.49) EPS for the quarter, missing the Zacks' consensus estimate of ($0.20) by $0.29. View Spring Bank Pharmaceuticals' earnings history.

4 Wall Street analysts have issued 1-year target prices for Spring Bank Pharmaceuticals' shares. Their forecasts range from $1.50 to $2.00. On average, they anticipate Spring Bank Pharmaceuticals' stock price to reach $1.73 in the next year. This suggests a possible upside of 5.1% from the stock's current price. View analysts' price targets for Spring Bank Pharmaceuticals.

News coverage about SBPH stock has trended somewhat positive on Sunday, InfoTrie Sentiment Analysis reports. The research group identifies positive and negative media coverage by analyzing more than six thousand news and blog sources. The firm ranks coverage of public companies on a scale of negative five to positive five, with scores closest to five being the most favorable. Spring Bank Pharmaceuticals earned a media sentiment score of 2.0 on InfoTrie's scale. They also gave media stories about the company a news buzz of 0.0 out of 10, indicating that recent media coverage is extremely unlikely to have an impact on the stock's share price in the near term. View the latest news aboutSpring Bank Pharmaceuticals.

Spring Bank Pharmaceuticals saw a decline in short interest in the month of May. As of May 15th, there was short interest totaling 36,900 shares, a decline of 26.9% from the April 30th total of 50,500 shares. Based on an average daily volume of 170,400 shares, the short-interest ratio is presently 0.2 days. Approximately 0.2% of the company's stock are sold short. View Spring Bank Pharmaceuticals' Current Options Chain.

Some companies that are related to Spring Bank Pharmaceuticals include AcelRx Pharmaceuticals (ACRX), Catabasis Pharmaceuticals (CATB), Cyclerion Therapeutics (CYCN), ESSA Pharma (EPIX), Recro Pharma (REPH), TapImmune (MRKR), Galmed Pharmaceuticals (GLMD), TFF Pharmaceuticals (TFFP), Corvus Pharmaceuticals (CRVS), Eton Pharmaceuticals (ETON), Genprex (GNPX), Oncolytics Biotech (ONCY), Aptorum Group (APM), Sesen Bio (SESN) and CV Sciences (CVSI). View all competitors.

Based on aggregate information from My MarketBeat watchlists, some companies that other Spring Bank Pharmaceuticals investors own include Intelsat (I), AMC Entertainment (AMC), Bank of America (BAC), Fossil Group (FOSL), Associated British Foods (ABF), Apollo Global Management (APO), Chaarat Gold (CGH), SCYNEXIS (SCYX), China Unicom (Hong Kong) (CHU) and Ciena (CIEN).

(SBPH) raised $14 million in an initial public offering on Friday, May 6th 2016. The company issued 1,100,000 shares at a price of $12.00-$14.00 per share. Dawson James Securities acted as the underwriter for the IPO.

Spring Bank Pharmaceuticals trades on the NASDAQ under the ticker symbol "SBPH."

Spring Bank Pharmaceuticals' stock is owned by a number of institutional and retail investors. Top institutional shareholders include Tiedemann Advisors LLC (2.14%), Parsons Capital Management Inc. RI (0.49%), Exane Derivatives (0.49%), JPMorgan Chase & Co. (0.29%), Bank of New York Mellon Corp (0.27%) and Acadian Asset Management LLC (0.20%). Company insiders that own Spring Bank Pharmaceuticals stock include Jonathan Freve, Martin J Driscoll and Scott Andrew Smith. View institutional ownership trends for Spring Bank Pharmaceuticals.

SBPH stock was sold by a variety of institutional investors in the last quarter, including Tiedemann Advisors LLC, and Parsons Capital Management Inc. RI. View insider buying and selling activity for Spring Bank Pharmaceuticals.

SBPH stock was bought by a variety of institutional investors in the last quarter, including Exane Derivatives, JPMorgan Chase & Co., Bank of New York Mellon Corp, and Acadian Asset Management LLC. Company insiders that have bought Spring Bank Pharmaceuticals stock in the last two years include Jonathan Freve, Martin J Driscoll, and Scott Andrew Smith. View insider buying and selling activity for Spring Bank Pharmaceuticals.

Shares of SBPH can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

One share of SBPH stock can currently be purchased for approximately $1.65.

Spring Bank Pharmaceuticals has a market capitalization of $28.20 million. The company earns $-24,100,000.00 in net income (profit) each year or ($1.47) on an earnings per share basis. Spring Bank Pharmaceuticals employs 29 workers across the globe.

The official website for Spring Bank Pharmaceuticals is www.springbankpharm.com.

Spring Bank Pharmaceuticals' mailing address is 35 PARKWOOD DRIVE SUITE 210, HOPKINTON MA, 01748. The company can be reached via phone at 508-473-5993 or via email at [email protected]